NASDAQ · Biotechnology

DRMA (DRMA) Stock

$1.10 -0.90% NASDAQ: DRMA Healthcare

Valuation

MetricValue
Price$1.10
Market Cap$749713
P/E Ratio-0.15
P/B Ratio0.14
P/S Ratio0.00
EPS (TTM)$-8.16
52-Week High$8.00
52-Week Low$1.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-133.33%
ROA-100.00%
ROCE-133.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-8.0M$-10.0M$-8.0M$-13.0M$-8.0M
Net Profit$-8.0M$-10.0M$-8.0M$-12.0M$-8.0M
EPS$-152.70$-139.20$-399.81$-80.32$-8.16
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.0M$7.0M$8.0M$4.0M$8.0M
Total Liabilities$2.0M$1.0M$2.0M$2.0M$2.0M
Cash$11.0M$6.0M$7.0M$3.0M$8.0M
Borrowings$0$0$0$0$0

Latest News

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 ACCESS Newswire · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-6.0M$-9.0M$-6.0M$-11.0M$-7.8B
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$12.1B
Net Cash Flow$10.0M$-5.0M$1.0M$-4.0M$4.4B
Free Cash Flow$-6.0M$-9.0M$-6.0M$-11.0M$-7.8B

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-974.62%
Quick Ratio7.00
Interest Coverage—
Return 1Y-82.19%
Return 3Y-99.45%
Return 5Y—

Ownership

Insiders Held24.82%
Institutions Held7.38%
Institutions Float Held9.81%
Institutional HolderSharesReport Date
Geode Capital Management, LLC48,3342026-03-31
UBS Group AG35,6082026-03-31
Welch & Forbes, LLC20,0002026-03-31
MCF Advisors LLC1,7322026-03-31
Tower Research Capital LLC (TRC)7162026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTL $0.77 +1.96% -0.12 $1.80M 0.00%
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
CARMCarisma Therapeutics, Inc. $0.01 -5.17% 0.01 $230148 0.00%
ELAB $0.92 +2.21% 0.00 $1.78M 0.00%
GTBP $0.29 -4.65% -0.07 $3.12M 0.00%

About DRMA

DRMA is led by CEO Gerald T. Proehl, employs 8 people, headquartered in US, publicly traded since 2021.

DRMA stock trades at $1.10 with a market capitalization of $749713. The stock is valued at a price-to-earnings (P/E) ratio of -0.15, price-to-book of 0.14, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.10 and $8.00, and currently trades 86.3% below its 52-week high.

On profitability, DRMA generates a return on equity (ROE) of -133.33%, return on capital employed of -133.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides